T. Rowe Price Investment Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,384,449 shares of ALNY stock, worth $1.12 Billion. This represents 0.64% of its overall portfolio holdings.
Number of Shares
4,384,449
Previous 3,139,254
39.67%
Holding current value
$1.12 Billion
Previous $863 Million
19.49%
% of portfolio
0.64%
Previous 0.52%
Shares
10 transactions
Others Institutions Holding ALNY
# of Institutions
673Shares Held
112MCall Options Held
943KPut Options Held
922K-
Capital World Investors Los Angeles, CA16.6MShares$4.26 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.27 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.45 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.79 Billion0.35% of portfolio
-
Wellington Management Group LLP Boston, MA4.2MShares$1.08 Billion0.19% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $31.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...